Literature DB >> 30099225

Impact of uterine fibroids on quality of life: a national cross-sectional survey.

Fernandez Hervé1, Ardaens Katty2, Queval Isabelle3, Solignac Céline4.   

Abstract

OBJECTIVE: To study clinical impact of symptomatic uterine fibroids on women's health-related perceived quality of life regarding several dimensions. STUDY
DESIGN: A prospective cross-sectional web-based survey was conducted from August 18th to September 2nd 2016 among the general French population of women. A total of 1287 French women over the age of 18, among which 302 reported symptomatic uterine fibroids were surveyed. Data concerning demographics, symptoms and health-related quality of life (HRQL) using the UFS-QoL questionnaire, an overall well-being score and overall discomfort score were collected.
RESULTS: Almost two thirds of surveyed women (n = 193; 64%) reported moderate to severe fibroid-related symptoms (symptom severity score between 40 and 100). The global HRQL score showed that 64% of women (n = 193) reported a moderate to very important impact of fibroids on quality of life (HRQL global score between 0 and 50). The worse HRQL scores were reported for concern (57.5 ± 26.7), energy (58.1 ± 23.2) and self-conscious subscales (63.4 ± 24.3). The mean overall well-being score was lower in women with symptomatic uterine fibroids (6.6 ± 1.7) than in women without (7.3 ± 1.5). The mean overall discomfort score rated by women with symptomatic uterine fibroid was 5.7 ± 2.5 with a score between 6 and 10 reported by 56% of them.
CONCLUSIONS: We observed that 64% of surveyed women reported a moderate to very important impact of fibroids on their quality of life. This perceived alteration of quality of life together with the severity of symptomatic fibroids have a significant impact on the overall level of discomfort perceived by women and on their personal quality of life.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Health-related quality of life (HRQL); Symptomatic uterine fibroids; Uterine fibroid symptom-quality of life questionnaire (UFS-QoL)

Mesh:

Year:  2018        PMID: 30099225     DOI: 10.1016/j.ejogrb.2018.07.032

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  8 in total

1.  A Novel Cryptic t(2;3)(p21;q25) Translocation Fuses the WWTR1 and PRKCE Genes in Uterine Leiomyoma With 3q- as the Sole Visible Chromosome Abnormality.

Authors:  Ioannis Panagopoulos; Kristin Andersen; Ludmila Gorunova; Ben Davidson; Francesca Micci; Sverre Heim
Journal:  Cancer Genomics Proteomics       Date:  2022 Sep-Oct       Impact factor: 3.395

Review 2.  Evidence-Based Management of Uterine Fibroids With Botanical Drugs-A Review.

Authors:  Masita Arip; Vi Lien Yap; Mogana Rajagopal; Malarvili Selvaraja; K Dharmendra; Sasikala Chinnapan
Journal:  Front Pharmacol       Date:  2022-06-22       Impact factor: 5.988

Review 3.  Evaluation of marketing authorization and clinical implementation of ulipristal acetate for uterine fibroids.

Authors:  Mei-An Middelkoop; Maria E de Lange; T Justin Clark; Ben Willem J Mol; Pierre M Bet; Judith A F Huirne; Wouter J K Hehenkamp
Journal:  Hum Reprod       Date:  2022-05-03       Impact factor: 6.353

4.  Burden of Uterine Fibroids: An African Perspective, A Call for Action and Opportunity for Intervention.

Authors:  P Igboeli; W Walker; A McHugh; A Sultan; A Al-Hendy
Journal:  Curr Opin Gynecol Obstet       Date:  2019-08-11

Review 5.  The Role of miRNA and Related Pathways in Pathophysiology of Uterine Fibroids-From Bench to Bedside.

Authors:  Michał Ciebiera; Marta Włodarczyk; Stanisław Zgliczyński; Tomasz Łoziński; Klaudia Walczak; Artur Czekierdowski
Journal:  Int J Mol Sci       Date:  2020-04-24       Impact factor: 5.923

Review 6.  The Evolving Role of Natural Compounds in the Medical Treatment of Uterine Fibroids.

Authors:  Michał Ciebiera; Mohamed Ali; Lillian Prince; Tia Jackson-Bey; Ihor Atabiekov; Stanisław Zgliczyński; Ayman Al-Hendy
Journal:  J Clin Med       Date:  2020-05-14       Impact factor: 4.241

Review 7.  Clinical Utility Of Elagolix As An Oral Treatment For Women With Uterine Fibroids: A Short Report On The Emerging Efficacy Data.

Authors:  Manuela Neri; Gian Benedetto Melis; Elena Giancane; Valerio Vallerino; Monica Pilloni; Bruno Piras; Alessandro Loddo; Anna Maria Paoletti; Valerio Mais
Journal:  Int J Womens Health       Date:  2019-10-22

8.  Anxiety, Depression, and Quality of Life After Procedural Intervention for Uterine Fibroids.

Authors:  Kedra Wallace; Elizabeth A Stewart; Lauren A Wise; Wanda Kay Nicholson; John Preston Parry; Shuaiqi Zhang; Shannon Laughlin-Tommaso; Vanessa Jacoby; Raymond M Anchan; Michael P Diamond; Sateria Venable; Amber Shiflett; Ganesa R Wegienka; George Larry Maxwell; Daniel Wojdyla; Evan R Myers; Erica Marsh
Journal:  J Womens Health (Larchmt)       Date:  2021-06-08       Impact factor: 2.681

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.